The Relationship of Treatment Modality in Alopecia Areata with Life Quality, Anxiety, and Depression

This study evaluated the impact of treatment on life quality, anxiety, and depression in 72 patients with alopecia areata, totalis, or universalis, aged 18-60, over six months. The Dermatology Life Quality Index (DLQI) and Short Form-36 (SF-36) were used to assess life quality, while the Hospital Anxiety and Depression Scale measured anxiety and depression risks. Results showed a decrease in DLQI scores, particularly in the systemic treatment group, although not statistically significant. SF-36 scores indicated improved life quality across all groups. Anxiety scores decreased, especially in the systemic treatment group, but this change was also not statistically significant. The study concluded that evaluating treatment effectiveness in alopecia areata should include changes in life quality and psychiatric risks, not just clinical outcomes.